Eli Lilly, the drugmaker of Zepbound, has announced that their popular weight loss drug may also be beneficial for individuals with obstructive sleep apnea. Obstructive sleep apnea is a condition characterized by brief pauses in breathing during sleep, leading to disrupted sleep patterns and potential health risks such as heart disease and stroke.
Recent trials have shown promising results, prompting Eli Lilly to consider seeking FDA approval to expand the use of Zepbound to include the treatment of obstructive sleep apnea. The drug, which contains tirzepatide as its active ingredient, was initially approved for obesity treatment and later for type 2 diabetes.
Studies conducted on adult patients with obesity and obstructive sleep apnea revealed significant improvements in sleep apnea symptoms among those treated with Zepbound compared to those who did not receive the drug. Participants also experienced weight loss, with a notable reduction in body weight observed in individuals taking the medication.
Notably, the trials demonstrated a substantial decrease in breathing events during sleep for individuals using Zepbound, particularly those who were unable or unwilling to use positive airway pressure (PAP) therapy. The drug's efficacy in reducing ectopic fat deposits around the airway, a key factor in obstructive sleep apnea, was also highlighted.
Dr. Daniel Skovronsky, Eli Lilly's chief scientific officer, expressed enthusiasm over the positive outcomes of the studies, emphasizing the potential of Zepbound to address the underlying causes of sleep apnea rather than merely providing symptomatic relief.
While the results are yet to undergo peer review and publication, Eli Lilly plans to present detailed findings at an upcoming medical conference. The company's ongoing evaluation of the data underscores the significance of these findings in potentially revolutionizing the treatment of obstructive sleep apnea.
Overall, the promising results of Zepbound in improving sleep apnea symptoms and promoting weight loss offer hope for individuals struggling with this prevalent sleep disorder. The potential expansion of Zepbound's usage to include obstructive sleep apnea could represent a significant advancement in the management of this condition.
